Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Halozyme Therapeutic 12390 EL CAMINO REAL SAN DIEGO CA 92130 USA

www.halozyme.com P: 858-794-8889 F: 858-704-8311

Description:

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.

Key Statistics

Overview:

Market Capitalization, $K 7,882,079
Enterprise Value, $K 9,262,959
Shares Outstanding, K 127,274
Annual Sales, $ 829,250 K
Annual Net Income, $ 281,590 K
Last Quarter Sales, $ 231,350 K
Last Quarter Net Income, $ 93,250 K
EBIT, $ 475,730 K
EBITDA, $ 561,570 K
60-Month Beta 1.28
% of Insider Shareholders 2.40%
% of Institutional Shareholders 97.79%
Float, K 124,219
% Float 97.60%
Short Volume Ratio 0.77

Growth:

1-Year Return 59.32%
3-Year Return 54.65%
5-Year Return 309.93%
5-Year Revenue Growth 446.06%
5-Year Earnings Growth 546.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.91 on 08/06/24
Next Earnings Date 11/04/24
Earnings Per Share ttm 3.00
EPS Growth vs. Prev Qtr 19.72%
EPS Growth vs. Prev Year 25.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

HALO Ratios

Ratio
Price/Earnings ttm 20.97
Price/Earnings forward 16.86
Price/Earnings to Growth 0.60
Return-on-Equity % 195.81%
Return-on-Assets % 21.07%
Profit Margin % 33.96%
Debt/Equity 5.19
Price/Sales 9.61
Price/Cash Flow 19.60
Price/Book 27.40
Book Value/Share 2.27
Interest Coverage 19.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar